10/18/2024

Janusmed sex and gender

Janusmed sex and gender – spironolactone

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Spironolactone

Spironolactone

Class : C

Show all info

Print

Contact us

  1. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3-15.

  2. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.

  3. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-5.

  4. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45.

  5. Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(3):384-90.

  6. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S et al. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens. 2008;21:976-82.

  7. Aldactone (spironolactone) DailyMed 2018. DailyMed [www]. US National Library of Medicine. [updated 2018-09-05, cited 2019-03-04].

  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.

  9. Opasich C, De Feo S, Ambrosio GA, Bellis P, Di Lenarda A, Di Tano G et al. The 'real' woman with heart failure Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail. 2004;6:769-79.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3-15.
  2. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61-6.
  3. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-5.
  4. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45.
  5. Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(3):384-90.
  6. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S et al. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens. 2008;21:976-82.
  7. Aldactone (spironolactone) DailyMed 2018. DailyMed [www]. US National Library of Medicine. [updated 2018-09-05, cited 2019-03-04].
  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
  9. Opasich C, De Feo S, Ambrosio GA, Bellis P, Di Lenarda A, Di Tano G et al. The 'real' woman with heart failure Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail. 2004;6:769-79.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]